Vidarbha News

Acute Respiratory Distress Syndrome Pipeline Landscape Analysis: 60+ Key Players & 60+ Pipeline Drugs

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome Pipeline Landscape Analysis: 60+ Key Players & 60+ Pipeline Drugs

November 16
22:40 2022
Acute Respiratory Distress Syndrome Pipeline Landscape Analysis: 60+ Key Players & 60+ Pipeline Drugs

DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Acute Respiratory Distress Syndrome Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Respiratory Distress Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report

  • DelveInsight’s Acute Respiratory Distress Syndrome Pipeline analysis depicts a robust space with 60+ active players working to develop 60+ pipeline treatment therapies.
  • The leading Acute Respiratory Distress Syndrome Companies are working such as Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others are developing potential drug candidates to improve the Acute Respiratory Distress Syndrome treatment scenario.
  • Promising Acute Respiratory Distress Syndrome Pipeline therapies such as MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, Glenzocimab, Gimsilumab, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Respiratory Distress Syndrome.

 

Get an overview of the pipeline landscape @ Acute Respiratory Distress Syndrome Clinical Trials Analysis

 

 

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of Acute Respiratory Distress Syndrome vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness. Along with medical history and physical examination, tests that help in diagnosis of Acute Respiratory Distress Syndrome are imaging tests, blood tests, and/or echocardiogram. Treatment options for Acute Respiratory Distress Syndrome include mechanical ventilation, fluid management, pharmacological treatment, extracorporeal lung support strategies, and other supportive measures. Gene therapy and stem cell therapy are under clinical investigation for the treatment of Acute Respiratory Distress Syndrome.

 

Recent Developmental Activities in the Acute Respiratory Distress Syndrome Pipeline

  • In February 2021, Athersys announced that it had entered into a cooperation agreement with HEALIOS. The cooperation agreement is intended to reaffirm the mutual commitment to the collaborative development of MultiStem in Japan.
  • In March 2021, Partner Therapeutics announced a licensing and collaboration agreement with SIRS Therapeutics and F4 Pharma to support the development of FX-06. This synthetic peptide has a broad spectrum of potential indications.
  • In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the US FDA awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.
  • In December 2020, The Food and Drug Administration (FDA) granted Fast Track designation to remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19).
  • In November 2020, Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L to treat acute respiratory distress syndrome.
  • In September 2020, Dimerix was awarded USD 1 million from the Australian Government’s BTB program to support the inclusion of DMX-200 in the REMAP-CAP global study.
  • In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for the acute respiratory distress syndrome (ARDS) program. In May 2019, US FDA granted Fast Track designation to MultiStem cell therapy for ARDS.
  • In June 2020, Quartesian announced a new partnership with Amyndas Pharmaceuticals for their Phase II clinical study evaluating the efficacy of AMY-101 in COVID-19 patients with acute respiratory distress syndrome (ARDS).

 

For further information, refer to the detailed Acute Respiratory Distress Syndrome Pipeline Therapeutics report @ Acute Respiratory Distress Syndrome Treatment Analysis

 

Acute Respiratory Distress Syndrome Pipeline Therapeutic Analysis

There are approx. 60+ key companies which are developing the therapies for Acute Respiratory Distress Syndrome. The companies which have their Acute Respiratory Distress Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Athersys.

 

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

  • Coverage- Global
  • Acute Respiratory Distress Syndrome Therapies Late-stage (Phase III) 
  • Acute Respiratory Distress Syndrome Therapies Mid-stage (Phase II)
  • Acute Respiratory Distress Syndrome Therapies Early-stage (Phase I)
  • Acute Respiratory Distress Syndrome Preclinical stage and Discovery candidates    
  • Acute Respiratory Distress Syndrome Discontinued and Inactive candidates 
  • Acute Respiratory Distress Syndrome Companies – Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others are developing potential drug candidates to improve the Acute Respiratory Distress Syndrome treatment scenario.
  • Acute Respiratory Distress Syndrome Pipeline therapies- MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, Glenzocimab, Gimsilumab, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Respiratory Distress Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Respiratory Distress Syndrome – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Acute Respiratory Distress Syndrome Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Traumakine: Faron Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BIO-11006: BioMarck Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. GEn1E-1124: GEn1E Lifesciences
  17. Drug profiles in the detailed report…..
  18. Preclinical/Discovery Stage Products
  19. IC 100: ZyVersa Therapeutics
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Acute Respiratory Distress Syndrome Key Companies
  23. Acute Respiratory Distress Syndrome Key Products
  24. Acute Respiratory Distress Syndrome- Unmet Needs
  25. Acute Respiratory Distress Syndrome- Market Drivers and Barriers
  26. Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
  27. Acute Respiratory Distress Syndrome Analyst Views
  28. Acute Respiratory Distress Syndrome Key Companies
  29. Appendix

 

Dive deep into rich insights into new Acute Respiratory Distress Syndrome Emerging Therapies, visit @ Acute Respiratory Distress Syndrome Drugs

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/